Corline Biomedical AB
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company's products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. Its products … Read more
Corline Biomedical AB (CLBIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.029x
Based on the latest financial reports, Corline Biomedical AB (CLBIO) has a cash flow conversion efficiency ratio of -0.029x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.20 Million) by net assets (Skr77.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Corline Biomedical AB - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Corline Biomedical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Corline Biomedical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corline Biomedical AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SILVER DOLLAR RES
F:4YW
|
N/A |
|
Nasus Pharma Ltd.
NYSE MKT:NSRX
|
N/A |
|
Secova Metals Corp
OTCQB:SEKZF
|
-0.162x |
|
Eyesvision Corp
KQ:031310
|
-0.027x |
|
Silverline Endustri ve Ticaret AS
IS:SILVR
|
-0.012x |
|
TRANSDIGM
BE:T7D
|
-0.091x |
|
Konsortium Transnasional Bhd
KLSE:4847
|
-0.286x |
|
Two Hands Corp
PINK:TWOH
|
0.044x |
Annual Cash Flow Conversion Efficiency for Corline Biomedical AB (2013–2024)
The table below shows the annual cash flow conversion efficiency of Corline Biomedical AB from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr86.91 Million | Skr-8.64 Million | -0.099x | -1146.88% |
| 2023-12-31 | Skr93.32 Million | Skr886.00K | 0.009x | +113.92% |
| 2022-12-31 | Skr94.59 Million | Skr-6.45 Million | -0.068x | -30.12% |
| 2021-12-31 | Skr92.23 Million | Skr-4.83 Million | -0.052x | +46.16% |
| 2020-12-31 | Skr52.03 Million | Skr-5.07 Million | -0.097x | +58.27% |
| 2019-12-31 | Skr59.32 Million | Skr-13.84 Million | -0.233x | -212.44% |
| 2018-12-31 | Skr54.96 Million | Skr-4.10 Million | -0.075x | +31.11% |
| 2017-12-31 | Skr45.93 Million | Skr-4.98 Million | -0.108x | +41.76% |
| 2016-12-31 | Skr38.75 Million | Skr-7.21 Million | -0.186x | +6.53% |
| 2015-12-31 | Skr21.25 Million | Skr-4.23 Million | -0.199x | +52.91% |
| 2014-12-31 | Skr5.48 Million | Skr-2.32 Million | -0.423x | -22.53% |
| 2013-12-31 | Skr8.00 Million | Skr-2.76 Million | -0.345x | -- |